New Study: Probiotic DE111® Found to Support Cardiovascular Health

Deerland Probiotics & Enzymes announces advancements in cardiovascular science and probiotic research in latest published study.

KENNESAW, GA (November 10, 2020) - Deerland Probiotics and Enzymes has announced the publication of a clinical study demonstrating efficacy of the probiotic Bacillus subtilis DE111® in promoting healthy endothelial function and support of healthy cholesterol levels.

The study, “Bacillus subtilis DE111 intake may improve blood lipids and endothelial function in healthy adults” published in Beneficial Microbes, was performed at a leading university specializing in probiotics research and is an IRB-approved, randomized, double-blind, placebo-controlled four-week trial involving 43 participants aged 18 to 65.

The overall goal of this parallel arm trial was to determine if various cardiovascular markers improved in healthy participants. The criterion for probiotic supplementation. This new research was based on findings from previous studies that showed clear correlations between certain probiotic strains and healthy vascular function, reduced systemic inflammation and glucose tolerance, as well as evidence that the species Bacillus subtilis can support healthy cholesterol levels with positive cardiovascular effects in animal models.

The research team found that B. subtilis DE111 supplementation of 1 billion CFU per day resulted in significant reduction in total cholesterol and non-HDL cholesterol relative to baseline measures. The team also observed a strong trend toward reduction in LDL cholesterol, as well as improvement in endothelial function: reactive hyperemia index (RHI), an indicator of blood flow and heart health, increased by 9.14%.

“To our knowledge, this is the first randomized controlled trial to investigate the effects of B. subtilis supplementation on these parameters in a human population,” the principal investigators of the study stated. The authors of the study believe that B. subtilis supplementation may have an indirect effect on enhancing the generation of short chain fatty acids (SCFA) leading to this cholesterol lowering effect.

“Nocturnally, these effects were observed in a population of healthy individuals, and the results strongly suggest that B. subtilis supplementation may help support cardiovascular health,” commented Dr. John Deaton, vice president of science and technology at Deerland.

Deaton added that the spore-forming properties of the probiotic DE111® allow formulating in a wide array of attractive consumer products even beyond traditional supplement capsules, including gummies, chocolates, functional beverages and fitness nutrition powders.

---

Deerland Probiotics & Enzymes, based in Kennesaw, Ga., specializes in developing science-backed solutions that benefit microbiome health, using probiotic, prebiotic and enzyme technology. The company offers a line of unique, clinically validated branded products, including DE111®, PreforPro®, ProHydrolase®, Solarplast®, Glutalytic® and Bifidolac® probiotic strains. Deerland collaborates with customers to develop innovative and often proprietary solutions in the dietary supplement, food and beverage, sports nutrition, and companion animal markets. In addition to branded ingredients and customized formulations, Deerland offers full turnkey products for private label through its YourBrand® portfolio. The company’s manufacturing services include bulk blends, capsules, stick packs and tablets, as well as bottling and labeling. To contact Deerland Probiotics & Enzymes, call 800.697.8179 or visit www.deerland.com.